Drugmakers from Pfizer to GSK to hike US prices on over 200 drugs, as prescription drug prices become a hot 2020 campaign topic

FILE PHOTO: The logo of U.S. pharmaceutical corporation Pfizer Inc. is seen at a branch in Zurich, Switzerland October 2, 2018. REUTERS/Arnd WiegmannReuters

  • Drugmakers including Pfizer Inc, GlaxoSmithKline PLC, and Sanofi SA are planning to hike US list prices on more than 200 drugs in the United States on Wednesday, according to drugmakers and data analyzed by healthcare research firm 3 Axis Advisors.
  • Nearly all of the price increases will be below 10%, and around half of them are in the range of 4 to 6%, said 3 Axis co-founder Eric Pachman. The median price increase is around 5%, he said.
  • More price increases are expected to be announced later this week, which could affect the median and range.
  • Soaring US prescription drug prices are expected to again be a central issue in the presidential election. President Donald Trump, who made bringing them down a core pledge of his 2016 campaign, is running for re-election in 2020.
  • GlaxoSmithKline said it will raise prices on more than 30 drugs. The company will raise prices on the blockbuster respiratory treatments it delivers through its Ellipta inhaler, its recently acquired cancer drug Zejula and on several products in its HIV-focused ViiV joint venture, according to 3 Axis Advisors.
  • Visit Business Insider's homepage for more stories.

NEW YORK (Reuters) - Drugmakers including Pfizer Inc <PFE.N>, GlaxoSmithKline PLC <GSK.L> and Sanofi SA <SASY.PA> are planning to hike U.S. list prices on more than 200 drugs in the United States on Wednesday, according to drugmakers and data analyzed by healthcare research firm 3 Axis Advisors.

Nearly all of the price increases will be below 10%, and around half of them are in the range of 4 to 6%, said 3 Axis co-founder Eric Pachman. The median price increase is around 5%, he said.

See the rest of the story at Business Insider

See Also:



from Feedburner https://ift.tt/2ssIg8X
via IFTTT

Comments

Post a Comment

Popular posts from this blog

Autonomation

Image
“Jidoka” is a new one to me. TRI (Toyota Research Institute) CEO Gill Pratt described the concept as “Automation with a Human Touch.” The anglicized version of the notion is “Autonomation” — both are modified forms of “ automation,” in their respective languages. The word was originally applied to Toyota’s Production System, highlighting the need for human participation in the process. Quoting from Toyota here: Employing Jidoka principles throughout the production process is a vital element of the Toyota Production System, forcing imperfections to be immediately addressed by self-inspecting workers and thereby reducing the amount of work added to a defective product. Some automated machines can also function in the detection process, allowing human operatives to only be engaged when alerted to a problem. It’s a nice sentiment — a kind of harmony between robots and humans that ultimately plays to their respective strengths. There is, of course, a very real question of how fundamen
Read more

Tesla’s Dojo, a timeline

Elon Musk doesn’t want Tesla to be just an automaker. He wants Tesla to be an AI company, one that’s figured out how to make cars drive themselves.  Crucial to that mission is Dojo, Tesla’s custom-built supercomputer designed to train its Full Self-Driving (FSD) neural networks. FSD isn’t actually fully self-driving; it can perform some […] © 2024 TechCrunch. All rights reserved. For personal use only. from TechCrunch https://ift.tt/9uhRcnY via IFTTT
Read more

Time for moderation?

Flexport CEO Ryan Petersen made it clear that while he was keen on buying Convoy because of the "incredible tech stack" it built, he wasn't buying its strategy. © 2023 TechCrunch. All rights reserved. For personal use only. from TechCrunch https://ift.tt/oB8wO3Q via IFTTT
Read more